RECENT DEVELOPMENTS IN THE TREATMENT OF DYSLIPIDEMIA

Plasma lipids represent a major determinant for the development of cor onary heart disease (CHD) and thus mortality in the industrialised wor ld. Drug therapies that alter lipid levels have continued to demonstra te a mortality benefit in certain types of dyslipidaemia. Many enterpr ises are pursuing further agents that reduce the risk of CHD-events by established as well as novel mechanisms. This review provides a summa ry of the patents filed for such endeavours over the preceding two yea rs.